Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 FY26 Earnings Call

Shasta pivotal data support potential SHTG expansion, with FDA sNDA submission planned by year-end 2026 [20][34].

Q3 FY26 results, source: company transcript and SEC filings
QuarterQ3 FY26
Call date2026-08-04
Length59 minutes
EPS$-1.36
EPS consensus$-1.23
Revenue$75.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All ARWR earnings ยท Back to ARWR overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.